Yash R Somnay1, Eric Weinlander1, David F Schneider1, Rebecca S Sippel1, Herbert Chen2. 1. Section of Endocrine Surgery, Division of General Surgery, Department of Surgery, University of Wisconsin, Madison, WI. 2. Section of Endocrine Surgery, Division of General Surgery, Department of Surgery, University of Wisconsin, Madison, WI. Electronic address: chen@surgery.wisc.edu.
Abstract
INTRODUCTION: Tertiary hyperparathyroidism (3HPTH) patients who undergo parathyroidectomy (PTX) are often managed with calcium lowering medications such as cinacalcet (Sensipar) before surgery. Here, we assess how cinacalcet treatment influences intraoperative parathyroid hormone (IOPTH) kinetics and surgical findings in 3HPTH patients undergoing PTX. METHODS: We reviewed retrospectively 113 patients 3HPTH who underwent PTX, 14 of whom were taking cinacalcet and 112 who were not taking the drug. IOPTH levels fitted to linear curves versus time were used to evaluate the role of cinacalcet. RESULTS: Cinacalcet did not correlate with rates of cure (P = .41) or recurrence (P = .54). Patients taking cinacalcet experienced a steeper decrease in IOPTH compared with those not taking the medication (P = .005). Cinacalcet treatment was associated with an increase in rate of hungry bones (P = .04). Weights of the heaviest glands resected (P = .02) and preoperative PTH levels (P = .0004) were greater among patients taking cinacalcet. CONCLUSION: Perioperative cinacalcet treatment in patients with 3HPTH alters IOPTH kinetics by causing a steeper decrease in IOPTH, but does not require modification of the standard IOPTH protocol. Although cinacalcet use does not adversely affect cure rates, it is associated with greater preoperative PTH and an increased incidence of hungry bones, hence serving as an indicator of more severe disease. Cinacalcet does not need to be held before operation.
INTRODUCTION:Tertiary hyperparathyroidism (3HPTH) patients who undergo parathyroidectomy (PTX) are often managed with calcium lowering medications such as cinacalcet (Sensipar) before surgery. Here, we assess how cinacalcet treatment influences intraoperative parathyroid hormone (IOPTH) kinetics and surgical findings in 3HPTHpatients undergoing PTX. METHODS: We reviewed retrospectively 113 patients3HPTH who underwent PTX, 14 of whom were taking cinacalcet and 112 who were not taking the drug. IOPTH levels fitted to linear curves versus time were used to evaluate the role of cinacalcet. RESULTS:Cinacalcet did not correlate with rates of cure (P = .41) or recurrence (P = .54). Patients taking cinacalcet experienced a steeper decrease in IOPTH compared with those not taking the medication (P = .005). Cinacalcet treatment was associated with an increase in rate of hungry bones (P = .04). Weights of the heaviest glands resected (P = .02) and preoperative PTH levels (P = .0004) were greater among patients taking cinacalcet. CONCLUSION: Perioperative cinacalcet treatment in patients with 3HPTH alters IOPTH kinetics by causing a steeper decrease in IOPTH, but does not require modification of the standard IOPTH protocol. Although cinacalcet use does not adversely affect cure rates, it is associated with greater preoperative PTH and an increased incidence of hungry bones, hence serving as an indicator of more severe disease. Cinacalcet does not need to be held before operation.
Authors: Frederic Triponez; Electron Kebebew; David Dosseh; Quan-Yang Duh; Marc Hazzan; Christian Noel; Glenn M Chertow; François Wambergue; Dominique Fleury; Vincent Lemaitre; Charles A G Proye; Orlo H Clark Journal: Surgery Date: 2006-12 Impact factor: 3.982
Authors: Andreas L Serra; Reto Savoca; Andreas R Huber; Urs Hepp; Aba Delsignore; Martin Hersberger; Rudolf P Wüthrich Journal: Nephrol Dial Transplant Date: 2006-09-27 Impact factor: 5.992
Authors: N Leca; M Laftavi; A Gundroo; R Kohli; I Min; J Karam; N Sridhar; G Blessios; R Venuto; O Pankewycz Journal: Am J Transplant Date: 2006-07-26 Impact factor: 8.086